Could a vaccine tame this rare brain disease?
NCT ID NCT07217665
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 3 times
Summary
This study tests a vaccine called AADvac1 in 146 people with progressive supranuclear palsy (PSP), a rare brain disorder that affects movement and thinking. The vaccine aims to target a protein linked to the disease and slow its progression. Participants will receive injections over time, and researchers will measure changes in symptoms using a rating scale.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AADvac1 (a vaccine targeting tau protein)
- What this could lead to
- If it works, this could slow the progression of PSP, a rare and devastating brain disease, giving patients more time with better function.
- What could go wrong
- This is an early Phase 2 trial with only 146 people, so results may not apply to all. The vaccine may not slow the disease or could cause side effects like injection reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSP - PROGRESSIVE SUPRANUCLEAR PALSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California, San Francisco (UCSF), Memory and Aging Center
San Francisco, California, 94158, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.